Wichita Urology Group, P.A.

Wichita, Kansas 67226

2 studies enrolling now · 4 studies all time

What they study most

Advanced Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Progressive Metastatic Castrate Resistant Prostate Cancer, Prostate Cancer, Prostatic Neoplasms

Studies at this site

• TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) — Recruiting now
• An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) — Recruiting now
• A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX — Completed
• A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer — Completed